Antimicrobial resistance incidence risk and factors among Helicobacter pylori-infected persons, United States

William M. Duck, Jeremy Sobel, Janet M. Pruckler, Qunsheng Song, David Swerdlow, Cindy Friedman, Alana Sulka, Balasubra Swaminathan, Tom Taylor, Mike Hoekstra, Patricia Griffin, Duane Smoot, Rick Peek, David C. Metz, Peter B. Bloom, Steven Goldschmid, Julie Parsonnet, George Triadafilopoulos, Guillermo I. Perez-Perez, Nimish Vakil & 4 others Peter Ernst, Steve Czinn, Donald Dunne, Ben D. Gold

Research output: Contribution to journalArticle

Abstract

Helicobacter pylori is the primary cause of peptic ulcer disease and an etiologic agent in the development of gastric cancer. H. pylori infection is curable with regimens of multiple antimicrobial agents, and antimicrobial resistance is a leading cause of treatment failure. The Helicobacter pylori Antimicrobial Resistance Monitoring Program (HARP) is a prospective, multicenter U.S. network that tracks national incidence rates of H. pylori antimicrobial resistance. Of 347 clinical H. pylori isolates collected from December 1998 through 2002, 101 (29.1%) were resistant to one antimicrobial agent, and 17 (5%) were resistant to two or more antimicrobial agents. Eighty-seven (25.1%) isolates were resistant to metronidazole, 45 (12.9%) to clarithromycin, and 3 (0.9%) to amoxicillin. On multivariate analysis, black race was the only significant risk factor (p <0.01, hazard ratio 2.04) for infection with a resistant H. pylori strain. Formulating pretreatment screening strategies or providing alternative therapeutic regimens for high-risk populations may be important for future clinical practice.

Original languageEnglish (US)
Pages (from-to)1088-1094
Number of pages7
JournalEmerging Infectious Diseases
Volume10
Issue number6
StatePublished - Jun 2004
Externally publishedYes

Fingerprint

Helicobacter pylori
Incidence
Anti-Infective Agents
Clarithromycin
Amoxicillin
Metronidazole
Helicobacter Infections
Treatment Failure
Peptic Ulcer
Stomach Neoplasms
Multivariate Analysis
Infection
Population

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Duck, W. M., Sobel, J., Pruckler, J. M., Song, Q., Swerdlow, D., Friedman, C., ... Gold, B. D. (2004). Antimicrobial resistance incidence risk and factors among Helicobacter pylori-infected persons, United States. Emerging Infectious Diseases, 10(6), 1088-1094.

Antimicrobial resistance incidence risk and factors among Helicobacter pylori-infected persons, United States. / Duck, William M.; Sobel, Jeremy; Pruckler, Janet M.; Song, Qunsheng; Swerdlow, David; Friedman, Cindy; Sulka, Alana; Swaminathan, Balasubra; Taylor, Tom; Hoekstra, Mike; Griffin, Patricia; Smoot, Duane; Peek, Rick; Metz, David C.; Bloom, Peter B.; Goldschmid, Steven; Parsonnet, Julie; Triadafilopoulos, George; Perez-Perez, Guillermo I.; Vakil, Nimish; Ernst, Peter; Czinn, Steve; Dunne, Donald; Gold, Ben D.

In: Emerging Infectious Diseases, Vol. 10, No. 6, 06.2004, p. 1088-1094.

Research output: Contribution to journalArticle

Duck, WM, Sobel, J, Pruckler, JM, Song, Q, Swerdlow, D, Friedman, C, Sulka, A, Swaminathan, B, Taylor, T, Hoekstra, M, Griffin, P, Smoot, D, Peek, R, Metz, DC, Bloom, PB, Goldschmid, S, Parsonnet, J, Triadafilopoulos, G, Perez-Perez, GI, Vakil, N, Ernst, P, Czinn, S, Dunne, D & Gold, BD 2004, 'Antimicrobial resistance incidence risk and factors among Helicobacter pylori-infected persons, United States', Emerging Infectious Diseases, vol. 10, no. 6, pp. 1088-1094.
Duck WM, Sobel J, Pruckler JM, Song Q, Swerdlow D, Friedman C et al. Antimicrobial resistance incidence risk and factors among Helicobacter pylori-infected persons, United States. Emerging Infectious Diseases. 2004 Jun;10(6):1088-1094.
Duck, William M. ; Sobel, Jeremy ; Pruckler, Janet M. ; Song, Qunsheng ; Swerdlow, David ; Friedman, Cindy ; Sulka, Alana ; Swaminathan, Balasubra ; Taylor, Tom ; Hoekstra, Mike ; Griffin, Patricia ; Smoot, Duane ; Peek, Rick ; Metz, David C. ; Bloom, Peter B. ; Goldschmid, Steven ; Parsonnet, Julie ; Triadafilopoulos, George ; Perez-Perez, Guillermo I. ; Vakil, Nimish ; Ernst, Peter ; Czinn, Steve ; Dunne, Donald ; Gold, Ben D. / Antimicrobial resistance incidence risk and factors among Helicobacter pylori-infected persons, United States. In: Emerging Infectious Diseases. 2004 ; Vol. 10, No. 6. pp. 1088-1094.
@article{8e031850b49c4fa897056f51eec5b06b,
title = "Antimicrobial resistance incidence risk and factors among Helicobacter pylori-infected persons, United States",
abstract = "Helicobacter pylori is the primary cause of peptic ulcer disease and an etiologic agent in the development of gastric cancer. H. pylori infection is curable with regimens of multiple antimicrobial agents, and antimicrobial resistance is a leading cause of treatment failure. The Helicobacter pylori Antimicrobial Resistance Monitoring Program (HARP) is a prospective, multicenter U.S. network that tracks national incidence rates of H. pylori antimicrobial resistance. Of 347 clinical H. pylori isolates collected from December 1998 through 2002, 101 (29.1{\%}) were resistant to one antimicrobial agent, and 17 (5{\%}) were resistant to two or more antimicrobial agents. Eighty-seven (25.1{\%}) isolates were resistant to metronidazole, 45 (12.9{\%}) to clarithromycin, and 3 (0.9{\%}) to amoxicillin. On multivariate analysis, black race was the only significant risk factor (p <0.01, hazard ratio 2.04) for infection with a resistant H. pylori strain. Formulating pretreatment screening strategies or providing alternative therapeutic regimens for high-risk populations may be important for future clinical practice.",
author = "Duck, {William M.} and Jeremy Sobel and Pruckler, {Janet M.} and Qunsheng Song and David Swerdlow and Cindy Friedman and Alana Sulka and Balasubra Swaminathan and Tom Taylor and Mike Hoekstra and Patricia Griffin and Duane Smoot and Rick Peek and Metz, {David C.} and Bloom, {Peter B.} and Steven Goldschmid and Julie Parsonnet and George Triadafilopoulos and Perez-Perez, {Guillermo I.} and Nimish Vakil and Peter Ernst and Steve Czinn and Donald Dunne and Gold, {Ben D.}",
year = "2004",
month = "6",
language = "English (US)",
volume = "10",
pages = "1088--1094",
journal = "Emerging Infectious Diseases",
issn = "1080-6040",
publisher = "Centers for Disease Control and Prevention (CDC)",
number = "6",

}

TY - JOUR

T1 - Antimicrobial resistance incidence risk and factors among Helicobacter pylori-infected persons, United States

AU - Duck, William M.

AU - Sobel, Jeremy

AU - Pruckler, Janet M.

AU - Song, Qunsheng

AU - Swerdlow, David

AU - Friedman, Cindy

AU - Sulka, Alana

AU - Swaminathan, Balasubra

AU - Taylor, Tom

AU - Hoekstra, Mike

AU - Griffin, Patricia

AU - Smoot, Duane

AU - Peek, Rick

AU - Metz, David C.

AU - Bloom, Peter B.

AU - Goldschmid, Steven

AU - Parsonnet, Julie

AU - Triadafilopoulos, George

AU - Perez-Perez, Guillermo I.

AU - Vakil, Nimish

AU - Ernst, Peter

AU - Czinn, Steve

AU - Dunne, Donald

AU - Gold, Ben D.

PY - 2004/6

Y1 - 2004/6

N2 - Helicobacter pylori is the primary cause of peptic ulcer disease and an etiologic agent in the development of gastric cancer. H. pylori infection is curable with regimens of multiple antimicrobial agents, and antimicrobial resistance is a leading cause of treatment failure. The Helicobacter pylori Antimicrobial Resistance Monitoring Program (HARP) is a prospective, multicenter U.S. network that tracks national incidence rates of H. pylori antimicrobial resistance. Of 347 clinical H. pylori isolates collected from December 1998 through 2002, 101 (29.1%) were resistant to one antimicrobial agent, and 17 (5%) were resistant to two or more antimicrobial agents. Eighty-seven (25.1%) isolates were resistant to metronidazole, 45 (12.9%) to clarithromycin, and 3 (0.9%) to amoxicillin. On multivariate analysis, black race was the only significant risk factor (p <0.01, hazard ratio 2.04) for infection with a resistant H. pylori strain. Formulating pretreatment screening strategies or providing alternative therapeutic regimens for high-risk populations may be important for future clinical practice.

AB - Helicobacter pylori is the primary cause of peptic ulcer disease and an etiologic agent in the development of gastric cancer. H. pylori infection is curable with regimens of multiple antimicrobial agents, and antimicrobial resistance is a leading cause of treatment failure. The Helicobacter pylori Antimicrobial Resistance Monitoring Program (HARP) is a prospective, multicenter U.S. network that tracks national incidence rates of H. pylori antimicrobial resistance. Of 347 clinical H. pylori isolates collected from December 1998 through 2002, 101 (29.1%) were resistant to one antimicrobial agent, and 17 (5%) were resistant to two or more antimicrobial agents. Eighty-seven (25.1%) isolates were resistant to metronidazole, 45 (12.9%) to clarithromycin, and 3 (0.9%) to amoxicillin. On multivariate analysis, black race was the only significant risk factor (p <0.01, hazard ratio 2.04) for infection with a resistant H. pylori strain. Formulating pretreatment screening strategies or providing alternative therapeutic regimens for high-risk populations may be important for future clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=2542580999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542580999&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 1088

EP - 1094

JO - Emerging Infectious Diseases

JF - Emerging Infectious Diseases

SN - 1080-6040

IS - 6

ER -